Treatment Action Group (TAG), along with partners, announced the release of two additional tools and resources to support advancing TB advocacy with national governments, in the context of the UN High-Level Meeting on TB taking place in September this year.

Treatment Action Group releases the spring issue of TAGline, Bend the curves: Activism and the elimination of HIV, HCV, and TB.

DR-TB STAT + TAG brief: Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis

The U.S. Division of AIDS (DAIDS) and its prevention and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) networks have a long history of including pregnant and lactating women in clinical trials and of developing research agendas that target long standing and new knowledge gaps necessary to meet the needs of this neglected population.

An innovative and important new TB resource – Know Your Rights: Tuberculosis Prevention, Diagnosis, and Treatment Guide.

In December 2017, Treatment Action Group (TAG), ACTION and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) conducted a webinar on the results of two phase III trials for treating rifampicin-resistant TB.

The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a webinar held on 12 December 2017. The webinar explored implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.

The symposium was held October 12 at the 2017 Union World Conference on Lung Health in Guadalajara, Mexico.

Exploring the implications of the delamanid phase III and STREAM trial results